Related Experiment Videos
[Two years experience with the Pericarbon stentless valve in Hungary]
Zsolt Nagy1, Annamária Bódi, Miklós Vaszily
1Debreceni Egyetem, Orvos- és Egészségtudományi Centrum, Altalános Orvostudományi Kar, Szívsebészeti Klinika.
Orvosi Hetilap
|November 19, 2002
Summary
The Sorin Pericarbon stentless valve offers excellent hemodynamic performance for elderly patients with aortic valve disease. This aortic valve replacement option resulted in improved functional class and reduced ventricular thickness post-surgery.
Area of Science:
- Cardiovascular Surgery
- Biomedical Engineering
- Geriatric Medicine
Background:
- Stentless heart valves were introduced in 1999 for aortic valve disease treatment in elderly patients.
- The University of Debrecen's Department of Cardiac Surgery adopted this technology.
Purpose of the Study:
- To evaluate the safety and efficacy of the Sorin Pericarbon stentless valve.
- To assess hemodynamic performance and clinical outcomes in elderly patients undergoing aortic valve replacement.
Main Methods:
- Aortic valve replacement using the Sorin Pericarbon stentless valve in 63 elderly patients (1999-2001).
- Preoperative assessment included gradients, left ventricular wall thickness, and ejection fraction.
- Surgical data included procedure type, clamp/perfusion times, and valve sizes implanted.
Main Results:
- Hospital mortality was 6%; transient atrial fibrillation was the most common complication.
- 77% of patients recovered uneventfully within a week.
- Follow-up showed 86% in NYHA Class I, with significantly reduced transvalvular gradients and left ventricular wall thickness.
Conclusions:
- The Sorin Pericarbon stentless valve is easily implantable.
- Excellent hemodynamic properties and no need for anticoagulation support its use in elderly patients.
- The valve replacement device demonstrates safe and effective outcomes in this patient cohort.